Advances towards the use of gastrointestinal tumor patient-derived organoids as a therapeutic decision-making tool

Advances towards the use of gastrointestinal tumor patient-derived organoids as a therapeutic decision-making tool

Abstract In December 2022 the US Food and Drug Administration (FDA) removed the requirement that drugs in development must undergo animal testing before clinical evaluation, a declaration that now demands the establishment and verification of ex vivo preclinical models that closely represent tumor c...

Full description

Bibliographic Details
Main Authors: Javiera Obreque, Luis Vergara-Gómez, Nicolás Venegas, Helga Weber, Gareth I. Owen, Pablo Pérez-Moreno, Pamela Leal, Juan Carlos Roa, Carolina Bizama
Format: Article
Language:English
Published: BMC 2023-12-01
Series:Biological Research
Subjects:
Patient-derived organoid
Gastrointestinal cancer
Pre-clinical model
Drug response prediction
Immunotherapy
Tumor microenvironment
Online Access:https://doi.org/10.1186/s40659-023-00476-9

Internet

https://doi.org/10.1186/s40659-023-00476-9

Similar Items